The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial.

Date publication

novembre 2020

Journal

European heart journal

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick

Tous les auteurs :
Cleland JGF, Ferreira JP, Mariottoni B, Pellicori P, Cuthbert J, Verdonschot JAJ, Petutschnigg J, Ahmed FZ, Cosmi F, Brunner La Rocca HP, Mamas MA, Clark AL, Edelmann F, Pieske B, Khan J, McDonald K, Rouet P, Staessen JA, Mujaj B, González A, Diez J, Hazebroek M, Heymans S, Latini R, Grojean S, Pizard A, Girerd N, Rossignol P, Collier TJ, Zannad F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33215209

Résumé

To investigate the effects of spironolactone on fibrosis and cardiac function in people at increased risk of developing heart failure.

Mots clés

Collagen markers, Fibrosis, Heart failure prevention, Spironolactone

Référence

Eur Heart J. 2020 Nov 20;: